Cellectis (CLLS) Competitors

Cellectis (NASDAQ:CLLS) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Which has more volatility and risk, CLLS or CYRX?

Cellectis has a beta of 3.06, indicating that its stock price is 206% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Does the MarketBeat Community favor CLLS or CYRX?

Cellectis received 167 more outperform votes than Cryoport when rated by MarketBeat users. However, 65.15% of users gave Cryoport an outperform vote while only 65.08% of users gave Cellectis an outperform vote.

Company	Underperform	Outperform
Cellectis	Outperform Votes 410 65.08%	Underperform Votes 220 34.92%
Cryoport	Outperform Votes 243 65.15%	Underperform Votes 130 34.85%

Does the media refer more to CLLS or CYRX?

In the previous week, Cellectis and Cellectis both had 3 articles in the media. Cellectis' average media sentiment score of 1.16 beat Cryoport's score of 0.45 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cryoport	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer CLLS or CYRX?

Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 357.52%. Cryoport has a consensus target price of $12.29, indicating a potential upside of 97.52%. Given Cellectis' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectis is more favorable than Cryoport.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cryoport	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Do institutionals and insiders hold more shares of CLLS or CYRX?

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 92.9% of Cryoport shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 10.1% of Cryoport shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is CLLS or CYRX more profitable?

Cryoport has a net margin of -70.08% compared to Cellectis' net margin of -234.39%. Cryoport's return on equity of -13.35% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-234.39%	-74.55%	-22.65%
Cryoport	-70.08%	-13.35%	-6.43%

Which has better earnings and valuation, CLLS or CYRX?

Cryoport has higher revenue and earnings than Cellectis. Cryoport is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$9.19M	9.25	-$101.06M	-$1.30	-1.18
Cryoport	$233.26M	1.32	-$99.59M	-$3.38	-1.84

Summary

Cellectis beats Cryoport on 9 of the 17 factors compared between the two stocks.